Ann: Investor Presentation, page-26

I agree with @SimonGr, getting doctors on board would be a very good idea. I guess because it's been approved by the TGA as over the counter you don't need to get a script. Hopefully, once they've got their most important products in terms of saving lives up and running they might have more time to look at this.

Unrelated, but just wondering what other people think about the use of the words "...Quarter 4 2020 run rate to continue into Q1 & Q2 2021..."? In the Investor Presentation of 22 Feb 21. Are they talking dollar values of Q4 of roughly USD2.3 million continuing into Q1 and Q2 2021 (ie USD$4.6 in total) or PCP increases in revenue for Q1 & Q2 2020 vs 2021 with the Q4 PCP increase being roughly 70% and that being applied to the Q1 & Q2 21 revenues. A big diference in revenues depending on how you interpret those comments. It's something I think NXS needs to clarify to the market IMHO DYOR. Unless of course someone else has already addressed this here?